Results 51 to 60 of about 26,268,552 (306)

Adaptive guidelines to inform first-line treatment recommendations for gonorrhea.

, 2022
Adaptive guidelines to inform first-line treatment recommendations for gonorrhea.
Reza Yaesoubi (207900), Joshua A. Salomon (8668311), Thomas L. Gift (8668305), Katherine Hsu (8668302), Sancta B. St. Cyr (12066240), Yonatan H. Grad (3123549), Ted Cohen (118302)   +6 more
core   +1 more source

Chemotherapy for Spinal Cord Intramedullary Pediatric Low‐Grade Glioma—A Systematic Literature Review

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Pediatric intramedullary low‐grade gliomas (PIMLGGs) are rare neoplasms that present unique clinical and management challenges. Although surgery remains the primary tool for tissue diagnosis and decompression, complete gross‐total resection is frequently unfeasible due to the infiltrative nature of these lesions.
Olga M. Sergeenko, Segev Gabay, Jonathan Roth, Amit Ringel, Rina Dvir, Shlomi Constantini   +5 more
wiley   +1 more source

Drug coverage in treatment of malaria and the consequences for resistance evolution--evidence from the use of sulphadoxine/pyrimethamine. [PDF]

, 2010
BACKGROUND\ud \ud It is argued that, the efficacy of anti-malarials could be prolonged through policy-mediated reductions in drug pressure, but gathering evidence of the relationship between policy, treatment practice, drug pressure and the evolution of ...
Abdulla, Salim, Bloland, Peter, Malisa, Allen L, Roper, Cally, Allen L Malisa, Salim Abdulla, Cally Roper, Patrick S Kachur, Peter Bloland, Hassan Mshinda, Kachur, Patrick S, Richard J Pearce, Pearce, Richard J, Mshinda, Hassan   +13 more
core   +1 more source

“We Cannot Talk as a Family”: Complexities of Survivorship Communication Among Hispanic/Latino Young Adult Survivors of Childhood Cancer, Parents, and Clinicians

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Young adult childhood cancer survivors (YA‐CCS) have an increased risk of treatment‐related health complications throughout their lives. Lifelong survivorship care is recommended, yet many YA‐CCS experience disruptions in care during pediatric‐to‐adult transitions and do not receive recommended survivorship care.
Kevin Shanchen Pu, Nicole Fernández‐Viña, Briana C. Martin‐Villa, Daniela Ramirez, Rebecca M. Lewinsohn, Mary Smith, Heidi Boynton, Lidia Schapira, Stephanie M. Smith   +8 more
wiley   +1 more source

Update on first-line treatment of advanced ovarian carcinoma

International Journal of Women's Health, 2013
Z Kemp,1 JA Ledermann1,21Department of Oncology, University College London Hospitals, 2University College London Cancer Institute, University College London, London, United KingdomAbstract: Despite the high response rate to first-line treatment of ...
Kemp Z, Ledermann JA
doaj  

Selecting first-line immunotherapy in advanced melanoma: Current evidence on efficacy across diverse patient populations

EJC Skin Cancer
Immunotherapy has dramatically changed the outcome for patients with advanced melanoma, with significant improvements in overall survival and potential cure for some.
Sophia Kreft, Tommaso Bosetti, Rebecca Lee, Paul Lorigan   +3 more
doaj   +1 more source

First-Line Treatment for Advanced Pancreatic Cancer

JOP : Journal of the pancreas, 2013
Metastatic pancreatic cancer is a rapidly fatal disease with few therapeutic options. The authors summarize four abstracts (#148, #233, #158, #291) presented at the 2013 ASCO Gastrointestinal Cancers Symposium which were focused on novel agents for metastatic pancreatic cancer.
Nishi, Kothari, Muhammad Wasif, Saif, Richard, Kim   +2 more
openaire   +2 more sources

Time to switch from first-line to second-line treatment.

, 2018
Time to switch from first-line to second-line treatment.
Qiang Shi (191722), Chien-Hsun Lee (3753640), Ko-Jen Li (730660), Carol L. Gaich (5071301), Wesley Furnback (5071307), Tamas Treuer (5071304), Bruce C. M. Wang (5071313), Wen-Shuo Wu (5071310), Chao-Hsiun Tang (4242457)   +8 more
core   +1 more source

Second-line treatment options in hepatocellular carcinoma [PDF]

, 2019
For many years, sorafenib has been the only approved systemic treatment for advanced hepatocellular carcinoma (HCC). For over a decade, randomized controlled trials exploring the efficacy of new drugs both in first- and second-line treatment have failed ...
Elisa Sperti, Zichi, C., Audisio, M., Donatella Marino, Clizia Zichi, Di Maio, M., Marco Audisio, Massimo Di Maio   +7 more
core   +1 more source

Classical Complement Pathway Inhibition in a Pediatric Patient With Refractory Immune Thrombocytopenia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Pediatric refractory immune thrombocytopenia (rITP) is generally characterized by persistent thrombocytopenia and failure to achieve a sustained response to multiple standard therapies. We report a 4‐year‐old female with congenital tufting enteropathy, post‐intestinal transplant patient on immunosuppressants, who developed severe rITP ...
Sarah Hsieh, Susmita Sarangi, Caileigh Pudela, Catherine M. Broome, Tara K. Suntum   +4 more
wiley   +1 more source